Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

NCT06375707 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

144

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS
DRUG: Ribociclib combined with NSAI±OFS

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]